Sandoz Inc. [clinicaltrials_resource:0f70dfce3dffef0054e844a3b4f3ad2f]
A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility [clinicaltrials:NCT00002006]A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia [clinicaltrials:NCT00002007]An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia [clinicaltrials:NCT00002008]A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia [clinicaltrials:NCT00002009]A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis [clinicaltrials:NCT00002016]A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea [clinicaltrials:NCT00002252]A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study. [clinicaltrials:NCT00002253]A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia [clinicaltrials:NCT00002258]A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine [clinicaltrials:NCT00002263]A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria [clinicaltrials:NCT00002268]Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions [clinicaltrials:NCT00857142]Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions [clinicaltrials:NCT00857428]Relative Bioavailability of a Fentanyl Patch [clinicaltrials:NCT00857753]A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules [clinicaltrials:NCT00858195]To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions [clinicaltrials:NCT00861939]Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions [clinicaltrials:NCT00864006]A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions [clinicaltrials:NCT00864981]A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions [clinicaltrials:NCT00865033]Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting Conditions [clinicaltrials:NCT00865176]Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed Conditions [clinicaltrials:NCT00865618]To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions [clinicaltrials:NCT00865670]Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions [clinicaltrials:NCT00866216]Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions [clinicaltrials:NCT00875966]To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions [clinicaltrials:NCT00881127]To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions. [clinicaltrials:NCT00881153]To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions [clinicaltrials:NCT00881179]To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions [clinicaltrials:NCT00881231]To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions [clinicaltrials:NCT00881400]To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions [clinicaltrials:NCT00881426]To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions [clinicaltrials:NCT00881634]To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions [clinicaltrials:NCT00881738]To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions [clinicaltrials:NCT00881855]To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions [clinicaltrials:NCT00882154]To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions [clinicaltrials:NCT00882570]To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions [clinicaltrials:NCT00882700]To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions [clinicaltrials:NCT00882882]To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions [clinicaltrials:NCT00883064]To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions [clinicaltrials:NCT00883155]To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed [clinicaltrials:NCT00883506]To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions [clinicaltrials:NCT00883883]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc. [clinicaltrials_resource:17a08dfadb10614608e1a25f944e02c9]Eric Mittleberg, Ph.D., VP Product Development, Sandoz Inc. [clinicaltrials_resource:188cb4d464a0e7abe6c2b7269526b0ac]Eric Mittleberg, VP Product Development, Sandoz Inc. [clinicaltrials_resource:68f7225f14bb8c961f0062241f6f2d96]
organization [clinicaltrials_vocabulary:organization]
Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair [clinicaltrials:NCT00927758]A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis [clinicaltrials:NCT01038427]Clinical Trial With Mesalamine 1g Suppositories [clinicaltrials:NCT01172444]A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis [clinicaltrials:NCT01279057]
source [clinicaltrials_vocabulary:source]
Sandoz Inc. [clinicaltrials_resource:0f70dfce3dffef0054e844a3b4f3ad2f]
Bio2RDF identifier
0f70dfce3dffef0054e844a3b4f3ad2f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0f70dfce3dffef0054e844a3b4f3ad2f
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:0f70dfce3dffef0054e844a3b4f3ad2f
title
Sandoz Inc.
@en
type
label
Sandoz Inc. [clinicaltrials_resource:0f70dfce3dffef0054e844a3b4f3ad2f]
@en